Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) received FDA Fast Track designation for VIR-5500 to treat late-line metastatic castration-resistant prostate cancer.
VIR-5500 is a PSMA-targeted, dual-masked T-cell engager, designed to direct immune cells against cancer cells. It is being co-developed with Astellas Pharma through a global collaboration. The drug is being evaluated in a Phase 1 study across six dose-expansion cohorts, covering treatment alone and combinations with other prostate cancer therapies. Vir described Phase 1 data reported earlier this year as showing generally good tolerability and promising anti-tumor activity.
The ongoing trial is open-label and non-randomized, meaning participants know the treatment received and are not randomly assigned to treatment groups. It assesses safety, how the drug behaves in the body and preliminary efficacy. Vir anticipates Phase 3 trials beginning in 2027.
Vir Biotechnology (VIR) appointed David Liu as Executive Vice President and Chief Medical Officer, effective October 12, 2026.
Liu will lead clinical development, medical affairs and regulatory affairs. He joins from Nuvation Bio, where he served as Chief Medical Officer, built and led its global clinical research and development organization, and supported approval of its first oncology therapy. He brings more than 25 years of experience in oncology discovery, development and global regulatory efforts. Vir's programs include a Phase 3 program for chronic hepatitis delta and a pipeline of cancer immunotherapies.
Vir Biotechnology (VIR) will present Phase 2 SOLSTICE data on elebsiran and tobevibart for chronic hepatitis delta on November 8, 2026.
Two oral presentations are scheduled at AASLD’s The Liver Meeting in Denver, held November 5–9. Tarik Asselah will present patterns of HDV RNA responses through Week 96. Upkar Gill will present a translational sub-study examining changes in natural killer cells within the liver during treatment.
Vir Biotechnology (VIR) appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.
Sawaf will lead the finance, IT and investor relations functions. He brings more than 20 years of biopharmaceutical experience and joins from Theravance Biopharma, where he served as CFO since 2023 and Senior Vice President of Operations Strategy since 2025. He joined Theravance in 2014 and previously held roles on the research and development and commercial finance teams at Gilead Sciences.
Vir Biotechnology (Nasdaq: VIR) announced that President and CEO Marianne De Backer will take part in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14 at 7:45 a.m. ET. A live webcast and a 30-day archive will be accessible via the company’s investor relations website.
Vir Biotechnology (Nasdaq: VIR) reported second quarter 2026 revenue of $238.9 million, primarily from license and collaboration revenue tied to a $240.0 million upfront payment from its new global strategic collaboration with Astellas. Net income was $80.1 million (basic EPS $0.48), compared with a net loss of $111.0 million a year earlier.
Vir ended the quarter with approximately $1.01 billion in cash, cash equivalents and investments, up about $198.5 million, including a $75 million equity investment from Astellas and a $48.0 million pass-through payment to Sanofi. R&D expenses rose to $135.3 million, mainly reflecting a $48.0 million milestone payment to Sanofi and higher CHD manufacturing costs, while SG&A increased to $30.2 million on one-time advisory and legal fees.
Clinically, Week 96 Phase 2 SOLSTICE data in chronic hepatitis delta showed elebsiran plus tobevibart achieved undetectable HDV RNA in 88% ITT (97% last observation carried forward) and was generally well tolerated. The Phase 3 ECLIPSE registrational program is fully enrolled, with ECLIPSE 1 topline data expected in Q4 2026. Vir and Astellas also advanced VIR-5500 in metastatic prostate cancer, initiating multiple Phase 1 monotherapy and combination dose-expansion cohorts. The company expects its cash resources to fund operations into the second half of 2028.
Vir Biotechnology (Nasdaq: VIR) announced a finance leadership transition. Senior Vice President and Chief Accounting Officer Brent Sabatini has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne will remain with the company through August 3 to support the transition while Vir conducts a comprehensive search for its next Chief Financial Officer.
Vir Biotechnology (Nasdaq: VIR) announced it will host a conference call on Wednesday, August 5 at 4:30 p.m. ET / 1:30 p.m. PT to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The call will be accessible via the Events & Presentations page on the Vir Biotechnology website.
Summary not available.
Vir Biotechnology (Nasdaq: VIR) will present new data from the Phase 2 SOLSTICE trial in chronic hepatitis delta at the EASL Congress 2026 in Barcelona, May 27-30, 2026.
The Week 96 efficacy and safety results in hepatitis delta are featured in an oral “Best of EASL 2026” session, and a Week 48 BMI subgroup analysis is highlighted in an EASL poster tour.